Evidence map›Paper›PMID 41660662›Full record

ArticleOpen forum infectious diseases2026

Effectiveness and Durability of the BNT162b2 KP.2 Vaccine Against COVID-19 Hospitalization and Emergency Department or Urgent Care Encounters in US Adults.

Sara Y Tartof, Timothy B Frankland, Jeff M Slezak, Bradley K Ackerson, Laura Puzniak

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sara Y TartofKaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.ORCID https://orcid.org/0000-0003-2336-8476
Timothy B FranklandKaiser Permanente Hawaii Center for Integrated Health Care Research, Honolulu, Hawaii, USA.
Jeff M SlezakKaiser Permanente Southern California Department of Research & Evaluation, Pasadena, California, USA.ORCID https://orcid.org/0000-0002-6108-9198
Bradley K AckersonSouthern California Permanente Medical Group, Harbor City, California, USA.ORCID https://orcid.org/0000-0002-0816-7345
Laura PuzniakPfizer Inc., Collegeville, Pennsylvania, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccine effectiveness of BNT162b2 KP.2 vaccine against COVID-19 hospital admissions was 49% (95% CI, 30-63) and 45% (95% CI, 35-54) against emergency department/urgent care encounters (vs no KP.2 vaccine at <3 months). Protection persisted >90 days from vaccination with some waning. Vaccine effectiveness remained high regardless of prior COVID-19 vaccination and among older adults.

Indexed as

BNT162b2 KP.2COVID-19durabilitySARS-CoV-2vaccine effectiveness

Identifiers

PMID41660662
PMCPMC12875108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.